Summary. Antibodies to the meningococcal serosubtype-specific P1.7,16 protein and its variable regions (VR) were analysed in 28 convalescent sera drawn 8-36 months after systemic meningococcal disease by immunoblotting and enzyme immunoassay (EIA) methods. EIA antigens were the meningococcal P1.7,16 protein, produced in Bacillus subtilis, and peptides covering its VRl (P1.7 region) and VR2 (P1.16 region) inserted into a bacterial penicillinase protein. In the immunoblotting method, three meningococcal reference strains were used; they expressed either the P1.7,16 protein, or only its VR1 or VR2 epitopes in their class 1 proteins. Both methods showed a strong IgG response in four sera to P1.7,16 and VR2, but not to VR1; 18 sera had no or weak anti-class 1 protein activity. The six remaining sera were positive only on blots. The VR2-specific sera had 30-fold higher bactericidal activity than those with negligible P1.7,16 responses. Previous vaccination of the patients with a B : 1 5 : P1.7,16 meningococcal vaccine was associated with a strong anti-P 1.7,16 and anti-VR2 booster response that declined with time. The subtype-specific antibody activity in some sera indicated colonisation after disease by meningococci with class 1 proteins different from the strain that had caused disease.
Introduction
The class 1 protein, encoded by the porA gene, is a major outer-membrane protein of Neisseria meningitidis and is expressed by most meningococcal isolates.1+2 Antigenic variations of the class 1 protein generate the serosu btype-specificity of meningococci. Comparison of porA genes and their deduced aminoacid sequences showed that this diversity is confined to two distinct variable regions, designated VR1 and VR2.3-7 Sequence information has led to a proposed topology of the class 1 protein with membranespanning p-strands intervened by surface-exposed loop ~fructures.~' * Epitope mapping studies have localised the VRl and VR2 regions to the apices of loops 1 and 4, respe~tively.*~~-~ Binding of subtypespecific monoclonal antibodies (MAbs) to these regions has been shown to be bactericidal in oitro and protective in an in-vivo animal model.loJ1 Loops 1 and 4 are immunodominant and induce bactericidal antibodies in mice immunised with whole ba~teria.'~*'~ Also, antisera raised by immunisation of rabbits with a cyclic peptide containing the surface-exposed loop 4 are bactericidal.' ' After immunisation of human volunteers with different meningococcal outer-mem brane vesicle (OMV) vaccines, the serum bactericidal activity appears to be associated with class 1 protein antib0dies.l'~~~ In a group of volunteers receiving a B: 15 :P1.7,16 OMV vaccine, the class 1 antibody response was mainly directed against the P1.16 determinant in VR2.l7q1* The class 1 protein antibodies in these vaccines contributed significantly to the serum bactericidal activity. l8 9 l9 In those studies, the VR specificity of the class 1 protein antibodies was scored on immunoblots with reference meningococci as antigens that expressed either the VRl or VR2 of the P1.7,16 protein in their class 1 pr~teins.~'?'~ Recently, the VR1 and VR2 regions of P1. 7, 16 have been inserted into a bacterial carrier protein, the penicillinase of Bacillus licheniformis (Airaksinen et al., unpublished data). The current study investigated whether similar results for the VR responses would be obtained and better quantitated in enzyme immunoassays (EIA) with these epitope-specific antigens and a recombinant P1.7,16 protein devoid of other meningococcal components. For this analysis, a set of late convalescent sera from patients with systemic meningococcal disease who participated in the Norwegian vaccine trial either as vaccinees, placebo controls or non-participants were used." The aim of this study was to compare the serum antibody levels in immunoblotting and EIA assays against P1.7,16 and its VRl and VR2, and then to determine the association between these antibody responses and the bactericidal titres of the sera.
Materials and methods

Meningococcal strains
Reference strains 44 
Human sera
The sera for this study were selected from a collection of99 late convalescent sera, drawn at least 6 months after systemic meningococcal disease, from participants in the Norwegian group B vaccination trial.23 All 99 sera were screened on immunoblots for binding to OMV from the vaccine strain 44/76 in the absence and presence of Empigen BB (Albright and Wilson, Cumbria) 0.15%, a detergent used for refolding of denatured antigens on blot^.^^,^^ Twentyeight sera were selected by the following criteria : (1) all with distinct antibody binding to P1.7,16 protein on blots; (2) detergent-dependent PI .7,16 binding; (3) weak binding, but irifection with a vaccine-like strain.
The patients were identified by their K-numbers,26 and all had apparently normal complement function.23 Eight of the patients had been vaccinated twice in 1988-89 with the QMV vaccine, eight had received aluminium hydroxide placebo vaccine, and I2 belonged to the non-participant group.2o Sera drawn 8-79 days after onset of disease (early convalescent sera) from 12 of the vaccinees and placebo controls were also analysed. EIA. This was performed as described earlier. 21 Briefly, flat-bottomed microtitration plates (Nunc, Roskilde, Denmark) were coated overnight at 37°C with protein 5 ,ug/ml in phosphate-buffered saline (PBS). Stock solutions of BacPl.7,16 and BacPl. 15 were kept at 1-6 mg/ml in SDS 0.1 YO. Sera and alkaline phosphatase-conjugated antibodies to human immunoglobulins IgG, IgM and IgA (Caltag Laboratories, San Francisco, CA, USA) were diluted in PBS containing fetal calf serum (Gibco, Paisley) 10%. Titres were expressed as sample dilutions that gave E = 0.3 measured at 405 nm after incubation for 30 min. The lowest serum dilution tested was in 1 in 100. Titres < 1000 indicated no or minor antibody activity, while titres of 1000-1 500 represented low antibody levels.
EIA an tigens
Bactericidal assay
Serum bactericidal activity was assayed in microtitration plates as described previ~usly.~' The wells contained two-fold dilutions of serum (starting at serum 50 YO), an inoculum of 70-80 cfu of strain 44/76 (B : 15 : PI .7,16) and human complement 25 %. The complement source gave no fall in cfu in the test strain after incubation for 30 min; and it showed no reaction with OMV from strain 44/76 on immunoblots. About 10% of the colonies of strain 44/76 expressed O P C .~~ Titres are given as the final serum dilution that gave > 50% killing of the inoculum. A titre of < 2 was assigned to sera with < 50 % killing at a 1 in 2 dilution. A positive standard serum was included in every second plate.
Results
Characterisation of the immune response to the class I protein
Immune responses to the P1.7,16 protein in 28 convalescent sera, drawn 8-36 months after invasive meningococcal disease, were characterised by EIA with three coating antigens: (1) denatured recombinant BacPl.7,16 produced in B. subtilis, (2) the P1.7 region from protein P1.7,16 inserted into the Bla carrier protein (Bla-VRl) and (3) the corresponding insert of the P1.16 region (Bla-VR2). Control antigens included the denatured recombinant BacPl .15 protein, expressing different subtypes in its VRs, and Bla without inserts. None of these antigens contained other components of meningococcal origin. EIA was performed with immunoglobulin class-specific reagents, but only IgG and not IgA or IgM antibodies to any of the above antigens were detected.
All sera were also analysed on immunoblots for their IgG antibody binding to denatured class 1 proteins in OMVs from four different strains. These were : (1) protein PI .7,16 from strain 44/76, (2) protein P1.7,l from strain MlO8O sharing the VRl-associated P1.7 subtypeepitope withP1.7,16, (3) proteinP1.12,16 from strain S3032 sharing the VR2-associated P 1.16 subtype epitope with P1.7,16, and (4) P1.15 from strain H355 having no surface-exposed epitopes in common with P1.7,16. As in EIA, the latter strain served as control for the subtype specificity of the antibody responses. The intensities of the immunoreactive class 1 bands were scored as described in Materials and methods.
The results obtained with the two methods were classified into three groups as shown in table I. Group 1 included four sera for which both methods gave identical and strong antibody responses, group 2 contained 18 sera that showed no or low antibody binding to protein P1.7,16 with both methods and group 3 contained six sera that were positive by immunoblot ting only.
The four sera in group 1 showed a high titre in EIA (range 3500-15000) with BacP1.7,16 protein. They also had high titres to Bla-VR2 (range 2400-7400), but none reacted with Bla-VRl. On blots, the same four sera reacted strongly (Scores 3-54) with both the P1.7,16 and P1.12,16 proteins, but not with the P1.7,l protein, indicating that the main antibody activity recognised the PI. 16 epitope in VR2 that was common to these two proteins. Thus, the results were fully parallel to those obtained in EIA. Lack of reaction with protein P1.15 in both methods (not shown in table I) also supported the subtype specificity of the IgG response.
Three of the patients in group 1 had been vaccinated 6-16 months before disease with the B: 15:P1.7,16 OMV vaccine, whereas one patient (K-194) had received the placebo vaccine (table I). Two of the patients had been infected with vaccine-like strains, another with a strain of different subtype (B : 15 : P1.12, 13a),32 and one with a strain not isolated by culture but shown by other assays to be serogroup B. 26 Sixteen of the 18 sera in group 2 showed no anti-P1.7,16 activity in EIA (table I) . Serum from patient K-106 displayed a low to medium titre with BacP1.7,16, Bla-VR1 and VR2. This serum also reacted with both BacP1.15 and Bla, indicating the presence of cross-reactive antibodies. The other serum with low BacP1.7,16 titre was drawn 8 months after disease from vaccinee K-2 17 infected with a vaccinelike strain. All 18 sera showed no or weak binding to the different subtype proteins in immunoblots (scores 0-1.5 with the three class 1 proteins). When incubated in the presence of the detergent Empigen BB, four of the group 2 sera (K-99, K-158, K-172 and K-188) bound with medium intensity to one or more of the class 1 proteins of the test strains. These strictly detergent-dependent antibody activities were probably directed against conformational epitopes on the class 1 proteins.
In conclusion, although 11 of the 18 patients in group 2, including two vaccinees, had been infected with vaccine-like strains expressing PI .7 or PI. 16 epitopes, no or weak P1.7,16 antibody levels were found by both methods in sera obtained 8-31 months after disease. The six sera in group 3 showed no activity in EIA, but reacted on immunoblots with the class 1 protein of one or more of the three test strains with scores of 2-3.5 (table I) . To obtain more information about the specificity of the class 1 protein response in these sera, they were also probed with other strains as shown in the figure. A figure) . Identical results were obtained when detergent was used for renaturation of the antigens. Because this serum showed no reaction with BacP1.7,16 in EIA, the antibodies might be directed against conformational epitopes on the P1.7,16 protein which were partially renatured in the absence of detergent during the blotting procedure.
In contrast to the various antibody specificities in these sera directed to different parts on P1.7,16, serum from patients K-57 and K-186 showed other subtypespecificities. Serum from patient K-57 bound only to PI. 12,16 and P 1.12,13a ( figure, panel F) . Therefore, its reaction with P1.12,16, shown in table I, was accounted for by antibodies against the P1.12 epitope expressed by these two strains. The binding of serum Vaccinee K-84 in group 2 had neither response in the early nor in the late convalescent samples, indicating that infection with the B : 4 : -strain did not increase the presumed initial P1.7,16-specific antibodies obtained by vaccination. Vaccinees K-217 and K-187, infected with vaccine-like strains, showed an initial response to both BacPl.7,16 and VR2, followed by a decrease to low antibody levels 8-1 1 months after disease. None of the sera had anti-VR1 activity.
K-186 to P1.7,l (table I) was apparently caused by antibodies recognising the P1.1. subtype epitope because of its reaction with the two different P1.1 subtype strains ( figure. panel G) . When the blot was incubated with Empigen BB to partially refold the denatured proteins. binding to other class 1 proteins was also observed (panel G'). This indicated that, in addition to the P1.I specific activity the serum also contained antibodies against common conformational epitopes on the class 1 proteins.
All 28 sera were also studied for cross-reacting antibodies to the P 1.15 protein. On blots, only five sera showed medium binding (scores 2-2.5) to the P1.15 protein. Four of these belonged to group 2, the other was from patient K-186, shown to have responses against common class 1 protein determinants. Two other sera in group 2 reacted with BacP1.15 in EIA with medium titres (2000 and 2100). One of those was from patient K-106, whose serum reacted with all bacillar antigens. Thus, distinct cross-reactive antibodies were not detected by any of the methods.
Kinetics of' the c.1us.r I response
The low levels of class 1 protein antibodies observed in most of the late convalescent sera might be caused by a decline in the antibody response to infection as shown recently by Guttormsen et al. with purified P 1.7.16 protein in EIA.34 Therefore, sera taken earlier Bacterial activity of the sera Serum bactericidal activity (SBA) was assayed with strain 44/76 as a test for functionally relevant antibodies (table 111) . The test strain expressed low levels of the Opc protein, so Opc antibodies contributed little to the bactericidal tit re^.^'.^^ The four sera in group 1 with the highest levels of VR2-specific antibodies also had the highest SBA titres-128-5 12, geometric mean titre (GMT) 256. The sera in group 2 with no or low P1.7,16 activity had a GMT of 8.6. Only four of these sera had titres >, 64. Among the group 3 sera, that from patient K-66 with both a P1.16 and P1.7 response on blots was the only one with a corresponding high titre. This group had a GMT of 18 . Except for that from patient K-209, the high-titre sera in groups 2 and 3 were all from patients infected with B : 15 : P1.7,16 strains. In conclusion, the group 1 sera had 30-fold and 14-fold higher SBA than those in groups 2 and 3, respectively .
Antibodies against meningococcal surface antigens
Antibody levels against meningococcal surface antigens in the late convalescent sera were quantitated in EIA with whole-cell preparations from B : 15 in contrast to all four sera in group 1. These data indicated an immune response to several different antigens exposed on the meningococcal cell surface, with antibodies to the class 1 protein playing a major role.
Discussion
This report describes the antibody response to the meningococcal P1.7,16 class 1 protein and its two major VRl (P1.7) and VR2 (P1.16) epitopes in sera from patients with systemic meningococcal disease. To our knowledge, this is the first attempt to quantitate the human antibody response to the VRs of the class 1 protein by subtype-specific antigens free of other meningococcal components. Previously, several investigators have studied the presence of anti-class 1 protein antibodies in human sera, by immunoblotting, [15] [16] [17] [35] [36] [37] gel irnrnunoradioas~ay,~* inhibition studies with murine MAbs39-41 and EIA with purified P1.7,l 6.34
Both EIA and immunoblotting assays were used in this study to measure antibodies against P1.7,16 and its VRs in late convalescent sera. As detailed above, the antigens in the two methods were different in that the former assay employed various recombinant proteins, whereas different meningococcal strains were used in the latter method. The two methods gave identical results for the antibody responses with 22 (79%) of the 28 sera. Four sera (group 1, table I) showed strong antibody binding to P1,7,16 and its VR2 epitope with both methods, whereas 18 sera (group 2, table I) displayed no or low antibody response to P1.7,16 by either method. No VRl response was observed. The distinct binding of group 1 sera to the P1.7,16 proteins, denatured by SDS in both assays, as well as to Bla-VR2, suggested a strong antibody response to linear epitopes. An immunodominance of the VR2 (P1.16) epitope in healthy vaccinees measured by the same immunoblotting method has been reported previ0us1y.l~~ l8
Six convalescent sera showed intermediate responses on blots but were negative in EIA (group 3, table I). Four of these had antibody specificities towards different determinants on P1.7,16. These responses included one serum with antibodies against VR2 (K-l87), one with antibodies against both VR1 and VR2 (K-66), one reacting only with certain VR2-subtype proteins (K-223), whereas one serum (K-4) bound only to P1.7,16 itself, but not to its VRs or to other class 1 proteins. The two remaining sera had antibodies reacting with subtypes P1.12 and P1.1. As the EIA antigens did not include peptide constructs corresponding to these subtypes, this assay was expected to be negative. Thus, the blotting method detected four sera with various responses to P1.7,16 that were not seen in EIA. This may indicate a higher sensitivity of the immunoblotting assay as seen for the sera from patients K-66 and K-187, or alternatively, as indicated by the binding patterns of sera K-4 and K-223, the antibodies may bind to conformational epitopes. These conformational epitopes were probably formed by partial refolding of the P1.7,16 protein during the assay and were distinct from those detected only when a renaturing detergent was used during the incubation^.^^ Three of the late sera with hgh levels of anti-P1.7,16 and anti-VR2 antibodies were from vaccinees (group 1, table I) who fell ill with meningococcal disease during the Norwegian protection trial.20 Among the 99 original late sera tested-which included sera from 10 of the 12 vaccine failures-these three were the only high-responding sera found. As only one of the nonvaccinated patients showed a similar antibody level, the results indicated that infection led to increased vaccine-induced class 1 protein antibody levels as reported previo~s1y.l~~ 34,37 Also the boosting effect of an unnoticed colonisation has to be considered, as demonstrated by the vaccinated patient K-80, who had only low levels of anti-PI .7,16 antibodies 45 days after infection with a strain of a different subtype protein (B : 15 : P l.l2,13a), but a high level 24 months later (table 11) .
Comparison of the anti-P1.7,16 and anti-VR2 levels in early and late convalescent sera from vaccinees infected with vaccine-like strains showed a distinct fall in these activities with time (table 11) . These findings supported a previous demonstration of a fall in anti-P1.7,16 antibodies in convalescent sera to baseline levels 6 weeks-12 months after disease. 34 Similarly to that study, we also observed only IgG but no IgA or IgM antibodies against P1.7,16. Although vaccination had primed the individuals for a strong antibody response on further contact with the P1.7,16 antigen, it was not sufficient to protect them against infection with vaccine-like strains, as previously
The non-vaccinated patients K-57, K-186 and K-223 were infected with B: 1kP1.7, C: 2a:P1.2 and B : 4: PI. 14 strains, respectively (table I) . Nevertheless, the blotting results showed that the main antibody activity in these sera was directed to the P1.12, P1.1 and P1.16 epitopes, respectively, unrelated to the subtype of the strains causing disease in these individuals. We believe that these antibody activities probably reflected colonisation in the period after disease by meningococci expressing other subtype proteins. As discussed above, the distinct P1.16 response in the late serum from vaccinee K-80 indicated carriage of a P1.16 strain boosting vaccine-induced antibodies. From the rapid decline of class 1 protein antibodies it is likely that the new carrier strains must 37 have been acquired not long before the late convalescent sera were drawn.
A recent study has shown that c. 25 YO of Norwegian teenagers are healthy carriers of meningococci, but that < 10 YO of the carrier isolates were representative of the strains responsible for most of the meningococcal disease in Norway.42 Generally, the possible colonising strains observed in the present study did not have subtypes similar to the strains causing disease. However, the strong P1.16 response in placebo control K-194. who was a culture-negative case, suggested that both the colonising and infecting strains expressed subtype Pl.16. This assumption was supported by PCR and DNA sequence analysis of cerebrospinal fluid from this patient, drawing during the disease episode. demonstrating infection with a subtype P1.( 7). 16 strain (D. A. Caugant, personal communication). So, similar to the results found for volunteers receiving group B protein vaccine^,^'.''^ group B infections did not appear to prevent later acquisition of meningococci.
The group 1 sera with the highest levels of P1.7,16-and VR2-specific antibodies had 30-fold higher SBA than the group 2 sera with low or no response towards the corresponding antigens, and 14-fold higher SBA than those in group 3 with activities directed against various linear and conformational class 1 protein epitopes. After vaccination of mice, VR2 epitopes
